CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial.
Xu Y, Zhang X, Xin D, Zhang J, Wang L, Fan Y, Chen B, Lei W, Qiu X, Jiang H, Xiao X, Huang L, Yu J, Yang X, Yang W, Zhu J, Qian W.
Xu Y, et al. Among authors: jiang h.
Cancer Immunol Res. 2025 Jan 9;13(1):23-34. doi: 10.1158/2326-6066.CIR-24-0051.
Cancer Immunol Res. 2025.
PMID: 39432745
Clinical Trial.